EUVIMEDEUVIMED entdecken
Crossref

Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling

Ekta Pardhi, Rahul Khemchandani, Avinash Pawar, Akash Kharwar, Gananadhamu Samanthula, Manoj Dandekar iD, Neelesh Kumar Mehra iD

ACS Applied Bio Materials · 2025

DOI: 10.1021/acsabm.5c01473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Ekta Pardhi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Rese…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents, Nanoparticles, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic AgentsNanoparticlesPyrazolesBiocompatible MaterialsMaleHumansBiological AvailabilitySolubilityParticle SizeApoptosisAnimalsDrug Screening Assays, AntitumorCell ProliferationMolecular Dynamics SimulationMaterials TestingSuspensionsCell Survival

Stichwörter der Autor:innen

darolutamidenanosuspensionprostate cancersimulationsoluplus

Substanzen

Antineoplastic AgentsdarolutamidePyrazolesBiocompatible MaterialsSuspensions

Autor:innen und Institutionen

  • Department of Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana 500 037, India.
  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana 500 037, India.
  • Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hyderabad 500 037, India.

ORCID-Profile: Manoj Dandekar, Neelesh Kumar Mehra

Zitieren

APA

Pardhi, E., Khemchandani, R., Pawar, A., Kharwar, A., Samanthula, G., Dandekar, M., & Mehra, N. K. (2025). Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01473

Vancouver

Pardhi E, Khemchandani R, Pawar A, Kharwar A, Samanthula G, Dandekar M, et al. Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c01473

BibTeX
@article{Pardhi2025,
  author = {Pardhi, Ekta and Khemchandani, Rahul and Pawar, Avinash and Kharwar, Akash and Samanthula, Gananadhamu and Dandekar, Manoj and Mehra, Neelesh Kumar},
  title = {Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling},
  journal = {ACS Applied Bio Materials},
  year = {2025},
  doi = {10.1021/acsabm.5c01473}
}
Kostenlos starten →